Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 5

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study

Pages
1399–1408
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Hysterectomy affects the histopathological structure of rat ovaries and PPAR-γ agonist-rosiglitazone improves the ovarian Doppler blood flow parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: To evaluate the effects of hysterectomy on rat ovaries and the possible protective role of peroxisome proliferatoractivated receptor gamma (PPAR-γ) agonist-rosiglitazone against ovarian reserve decrement.
📊
Key Findings & Data:Hysterectomy was performed (n = 15) in group 1 [H]; 1 mg/kg/day PPAR-γ agonist/rosiglitazone was used for 50 days after hysterectomy (n = 15) in group 2 [H + R]; a sham operation was performed (n = 15) in group 3 [control, C].
💡
Conclusion & Impact:Conclusion: Hysterectomy affects the histopathological structure of rat ovaries and PPAR-γ agonist-rosiglitazone improves the ovarian Doppler blood flow parameters.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: To evaluate the effects of hysterectomy on rat ovaries and the possible protective role of peroxisome proliferatoractivated receptor gamma (PPAR-γ) agonist-rosiglitazone against ovarian reserve decrement. Materials and methods: Forty-five adult Wistar albino rats were randomly divided into three groups. Hysterectomy was performed (n = 15) in group 1 [H]; 1 mg/kg/day PPAR-γ agonist/rosiglitazone was used for 50 days after hysterectomy (n = 15) in group 2 [H + R]; a sham operation was performed (n = 15) in group 3 [control, C]. Blood samples were collected for anti-Müllerian hormone (AMH) evaluation in all groups and simultaneous ovarian Doppler examination was performed in [H] and [H + R] groups before and after (50 days) hysterectomy. All animals were sacrificed to obtain ovaries for histological examination. Results: AMH levels were found to be significantly decreased at postoperative day 50 in all groups (P 0.05). In the ovarian Doppler blood flow analysis, all parameters were significantly decreased in group [H] (P 0.05) on postoperative day 50. Conclusion: Hysterectomy affects the histopathological structure of rat ovaries and PPAR-γ agonist-rosiglitazone improves the ovarian Doppler blood flow parameters.

🔖

Cite This Article

DİLBAZ, B., DÜNDAR, B., GÖKTOLGA, Ü., TAPISIZ, Ö. L., GÜNDOĞDU, B., MÜFTÜOĞLU, K. H., MÜLAZIMOĞLU, S. B. (2022). What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 5, 1399–1408. https://ajindex.com/articles/609762

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. American Journal of Obstetrics and Gynecology 1993
  2. 168 (3 Pt 1): 765-771. doi: 10.1016/s0002-9378(12)90816-9 2. Ranney B, Abu-Ghazaleh S. The future function and fortune of ovarian tissue which is retained in vivo during hysterectomy. American Journal of Obstetrics and Gynecology 1977
  3. 128 (6): 626-634. doi: 10.1016/0002-9378(77)90208-3 3. Chalmers C, Lindsay M, Usher D, Warner P, Evans D et al. Hysterectomy and ovarian function: levels of follicle stimulating hormone and incidence of menopausal symptoms are not affected by hysterectomy in women under age 45 years. Climacteric 2002
  4. 5 (4): 366-373. 4. Vuorento T, Maenpaa J, Huhtaniemi I. Follow-up of ovarian endocrine function in premenopausal women after hysterectomy by daily measurements of salivary progesterone. Clinical Endocrinology (Oxf) 1992
  5. 36 (5): 505-510. doi: 10.1111/j.1365- 2265.1992.tb02253.x 5. Hallqvist Everhov A, Bergmark K, Smedby KE, Lindén Hirschberg A, Flöter Rådestad A. Anti-Müllerian hormone in premenopausal women following treatment of uterine cervical cancer. Acta Obstetricia et Gynecologica Scandinavica 2014
  6. 93 (9): 949-953. doi: 10.1111/aogs.12448 6. Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F et al. Effect of hysterectomy with ovarian preservation on ovarian function. Obstetrics and Gynecology 2011
  7. 118 (6): 1271-1279. doi: 10.1097/AOG.0b013e318236fd12 7. Ware J. Measures for a New Era of Health Assessment. In: Stewart ALWJ, editor. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press
  8. pp. 3-11. 8. Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. American Journal of Epidemiology 2005
  9. 162 (11): 1089-1097. doi: 10.1093/aje/ kwi324 9. Wilson LF, Pandeya N, Byles J, Mishra GD. Hysterectomy and perceived physical function in middle-aged Australian women: a 20-year population-based prospective cohort study. Quality of Life Research 2018
  10. 27 (6): 1501-1511. doi: 10.1007/s11136- 018-1812-9 10. Laganà AS, Vitale SG, Nigro A, Sofo V, Salmeri FM et al. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives. International Journal of Molecular Sciences